May 20th 2025
Incorporating six independent predictive factors for malignant thyroid nodules with peripheral calcifications, an emerging ultrasound-based nomogram provided an 88.2 percent AUC in validation testing.
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
In a recent interview, C. Alberto Morales, M.D., discussed the impact of advances with CTA imaging and AI, and a shifting emphasis in cardiac risk stratification from stenosis to plaque burden.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
FDA Expands Approval of Cardiac Ultrasound Imaging Agent for Pediatric Patients
The only ultrasound enhancing agent that does not contain polyethylene glycol, Optison may now be utilized to enhance echocardiogram assessment of ventricular function in pediatric patients.
Study Questions Utility of Ultrafast Breast MRI for Challenging Lesions and Moderate/Marked BPE
New research findings suggest that image quality and lesion conspicuity are significantly lower with ultrafast breast MRI in comparison to standard dynamic contrast-enhanced breast MRI.